| Id: | acc0875 |
| Group: | 2sens |
| Protein: | PTEN |
| Gene Symbol: | PTEN |
| Protein Id: | P60484 |
| Protein Name: | PTEN_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr382 |
| Site Sequence: | EPDHYRYSDTTDSDPENEPFD |
| Disease Category: | Cancer |
| Disease: | Melanoma |
| Disease Subtype: | |
| Disease Cellline: | A375 |
| Disease Info: | |
| Drug: | chondroitin-4-sulfate(CHSA) |
| Drug Info: | Chondroitin-4-sulfate (CHSA) is a sulfated glycosaminoglycan commonly used as a dietary supplement to support joint health and alleviate symptoms of osteoarthritis by promoting cartilage integrity and reducing inflammation. |
| Effect: | modulate |
| Effect Info: | CHSA treatment increased the phosphorylation levels of AKT and PTEN in A375 and SK-MEL-5 cells and enhanced the cell proliferation rate. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 29547721 |
| Sentence Index: | 29547721_3-4 |
| Sentence: | "Here we report that chondroitin-4-sulfate (CHSA), a natural glycosaminoglycan approved as a dietary supplement used for osteoarthritis, selectively promotes the tumor growth potential of BRAF V600E-expressing human melanoma cells in patient- and cell line-derived xenograft mice and confers resistance to BRAF inhibitors. Mechanistically, chondroitin sulfate glucuronyltransferase (CSGlcA-T) signals through its product CHSA to enhance casein kinase 2 (CK2)-PTEN binding and consequent phosphorylation and inhibition of PTEN, which requires CHSA chains and is essential to sustain AKT activation in BRAF V600E-expressing melanoma cells." |
Sequence & Structure:
MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| PTEN-Ser294 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.741 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.738 | ||||||||
| GBM | |||||||||
| HNSC | 1.65 | ||||||||
| LUAD | -0.543 | ||||||||
| LUSC | 0.557 | ||||||||
| non_ccRCC | -1.263 | ||||||||
| PDAC | 0.989 | ||||||||
| UCEC | 0.088 | ||||||||
| PTEN-Ser364 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | 0.707 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.707 | ||||||||
| PTEN-Ser370 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -1.229 | ||||||||
| HGSC | |||||||||
| ccRCC | 0.576 | ||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | 1.014 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.361 | ||||||||
| PTEN-Ser467 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.471 | ||||||||
| COAD | |||||||||
| HGSC | -1.149 | ||||||||
| ccRCC | |||||||||
| GBM | 0.677 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTEN-Thr363 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | 0.707 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.707 | ||||||||
| PTEN-Thr366 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | 0.707 |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | -0.707 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 382 | D | Non-small cell lung cancer | Phosphorylation | 35240162 |
| T | 382 | U | Lymphocytic leukemia | Phosphorylation | 20576813 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| P60484 | PTEN | P | Thr382 | YSDT(ph)TDSDPENEPFDEDQHTQITK | A549 | Pictilisib | 4.1859 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
